Evidence map›Paper›PMID 31693429›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Laurie H Sehn, Alex F Herrera, Christopher R Flowers, Manali K Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhit Ozcan and 6 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07225439 (Phase I Clinical Trial of Rituximab), which is not on this map. Cited by 423 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
423citing papers in PubMed, 8 pooled it
56.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07225439 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

TypeinterventionalSponsorPaolo Caimi, MDRan2026 to 2027Enrolled15ConditionsNon Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell LymphomaArmsAllogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide
3 · Its place in the literature

Who cites it

423 citing papers in PubMed, 8 syntheses or guidelines pooled it, 748 citations in OpenAlex.

  1. Pooled it
  2. SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  18. Trial
  19. Trial
  20. Trial

363 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 10 countries.

Laurie H SehnBC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, Canada.
Alex F HerreraCity of Hope, Duarte, CA.
Christopher R FlowersWinship Cancer Institute of Emory University, Atlanta, GA.
Manali K KamdarUniversity of Colorado, Aurora, CO.
Andrew McMillanNottingham University Hospitals, Nottingham, United Kingdom.
Mark HertzbergPrince of Wales Hospital and University of NSW, Sydney, NSW, Australia.
Sarit AssoulineJewish General Hospital, Montreal, Quebec, Canada.
Tae Min KimSeoul National University Hospital, Seoul, South Korea.
Won Seog KimSamsung Medical Center, Seoul, South Korea.
Muhit OzcanAnkara University, Ankara, Turkey.
Jamie HirataGenentech, South San Francisco, CA.
Elicia PenuelGenentech, South San Francisco, CA.
Joseph N PaulsonGenentech, South San Francisco, CA.
Ji ChengF. Hoffman-La Roche, Mississauga, Ontario, Canada.
Grace KuGenentech, South San Francisco, CA.
Matthew J MatasarMemorial Sloan Kettering Cancer Center, New York, NY.
Roche (Canada) · CASeoul National University Hospital · KRAnkara University · TRCity of Hope · USEmory University · USMemorial Sloan Kettering Cancer Center · USNottingham University Hospitals NHS Trust · GBPrince of Wales Hospital · AURoche (Switzerland) · CHSeagen (Canada) · CASpinal Cord Injury BC · CAUniversity of Colorado Anschutz Medical Campus · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposePatients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component.

methodsSafety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort. Polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) was compared with bendamustine and rituximab (BR) in a randomly assigned cohort of patients with transplantation-ineligible R/R DLBCL (primary end point: independent review committee [IRC] assessed complete response [CR] rate at the end of treatment). Duration of response, progression-free survival (PFS), and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression methods.

resultsPola-BG and pola-BR had a tolerable safety profile. The phase Ib/II pola-BG cohort (n = 27) had a CR rate of 29.6% and a median OS of 10.8 months (median follow-up, 27.0 months). In the randomly assigned cohort (n = 80; 40 per arm), pola-BR patients had a significantly higher IRC-assessed CR rate (40.0%

conclusionPolatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorFemaleHumansImmunoconjugatesImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProgression-Free SurvivalAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBendamustine HydrochlorideBiomarkers, TumorImmunoconjugatesobinutuzumabpolatuzumab vedotin

Identifiers

PMID31693429
PMCPMC7032881
OpenAlexW2984927918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.